To determine whether any of the long-range EBNA3A/3C binding sites interact with the BCL2L11 promoter, we performed 3C analysis in a previously described BL cell-line series (BL31) (Anderton et al., 2008). Here, BCL2L11 is linked to Burkitt lymphoma.